Literature DB >> 22206859

Correlational study of the serum levels of the glial fibrillary acidic protein and neurofilament proteins in Parkinson's disease patients.

Wen Su1, Hai Bo Chen, Shu Hua Li, Dong Ying Wu.   

Abstract

OBJECTIVE: To investigate changes in the serum levels of the glial fibrillary acidic protein (GFAP) and neurofilament proteins (NFs) in patients with Parkinson's disease (PD) and to determine their clinical significance.
METHODS: In this study, 82 subjects were divided into 3 groups: the PD group, the acute cerebral infarction (ACI) group, and a normal control group. The serum levels of GFAP and NFs were measured using a sandwich ELISA assay.
RESULTS: The serum levels of GFAP and NFs were significantly higher in the PD and the ACI groups than in the normal control group (P<0.05). There was no significant difference between the PD group and the ACI group (P>0.05). The serum level of GFAP in the PD group had no significant correlation with duration of the disease or age (P>0.05). The serum level of NFs in the PD group was significantly correlated with duration of the disease and age (P<0.05).
CONCLUSIONS: The serum levels of GFAP and NFs were significantly higher in the PD group than in the normal group, indicating that astrocytic activity may remain elevated during the axonal degeneration that occurs over duration of the disease, although this activity is not specific to the disease.
Copyright © 2011 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22206859     DOI: 10.1016/j.clineuro.2011.11.002

Source DB:  PubMed          Journal:  Clin Neurol Neurosurg        ISSN: 0303-8467            Impact factor:   1.876


  8 in total

1.  Lithium prevents parkinsonian behavioral and striatal phenotypes in an aged parkin mutant transgenic mouse model.

Authors:  Christopher A Lieu; Colleen M Dewey; Shankar J Chinta; Anand Rane; Subramanian Rajagopalan; Sean Batir; Yong-Hwan Kim; Julie K Andersen
Journal:  Brain Res       Date:  2014-10-27       Impact factor: 3.252

Review 2.  Review on intermediate filaments of the nervous system and their pathological alterations.

Authors:  Claire Lépinoux-Chambaud; Joël Eyer
Journal:  Histochem Cell Biol       Date:  2013-06-08       Impact factor: 4.304

3.  Neuroimaging and biomarker evidence of neurodegeneration in asthma.

Authors:  Melissa A Rosenkranz; Douglas C Dean; Barbara B Bendlin; Nizar N Jarjour; Stephane Esnault; Henrik Zetterberg; Amanda Heslegrave; Michael D Evans; Richard J Davidson; William W Busse
Journal:  J Allergy Clin Immunol       Date:  2021-09-15       Impact factor: 10.793

Review 4.  Blood GFAP as an emerging biomarker in brain and spinal cord disorders.

Authors:  Ahmed Abdelhak; Matteo Foschi; Samir Abu-Rumeileh; John K Yue; Lucio D'Anna; Andre Huss; Patrick Oeckl; Albert C Ludolph; Jens Kuhle; Axel Petzold; Geoffrey T Manley; Ari J Green; Markus Otto; Hayrettin Tumani
Journal:  Nat Rev Neurol       Date:  2022-02-03       Impact factor: 44.711

5.  Serum Phosphorylated Neurofilament-Heavy Chain, a Potential Biomarker, is Associated With Peripheral Neuropathy in Patients With Type 2 Diabetes.

Authors:  Xiaona Qiao; Shuo Zhang; Weiwei Zhao; Hongying Ye; Yehong Yang; Zhaoyun Zhang; Qing Miao; Renming Hu; Yiming Li; Bin Lu
Journal:  Medicine (Baltimore)       Date:  2015-11       Impact factor: 1.889

6.  Blood Level of Glial Fibrillary Acidic Protein (GFAP) Does not Correlate With Disease Progression in a Rat Model of Familial ALS (SOD1G93A Transgenic).

Authors:  Jeremy Jeffrey; Hannah D'Cunha; Masatoshi Suzuki
Journal:  Front Neurol       Date:  2018-11-14       Impact factor: 4.003

7.  The Association Between Phosphorylated Neurofilament Heavy Chain (pNF-H) and Small Fiber Neuropathy (SFN) in Patients with Impaired Glucose Tolerance.

Authors:  Yu-Peng Li; Zhong-Qing Yan; Li-Ping Han; Ai-Li Yin; Jin-Yong Xu; Ya-Ran Zhai; Sai Hao; Lin Zhang; Yun Xie
Journal:  Diabetes Ther       Date:  2019-10-30       Impact factor: 2.945

Review 8.  Recent Evidence in Epigenomics and Proteomics Biomarkers for Early and Minimally Invasive Diagnosis of Alzheimer's and Parkinson's Diseases.

Authors:  Sonia Mayo; Julián Benito-León; Carmen Peña-Bautista; Miguel Baquero; Consuelo Cháfer-Pericás
Journal:  Curr Neuropharmacol       Date:  2021       Impact factor: 7.363

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.